Taking A Deep Breath: Novartis & Schering Split Respiratory Product Rights, Giving Novartis Indacaterol
Executive Summary
Novartis is building a respiratory franchise based around its promising chronic obstructive pulmonary disease drug QAB149 (indacaterol) and is taking steps to make sure the world knows it
You may also be interested in...
Pharmaceutical/Biotechnology Deal Statistics Quarterly, Q2 2010
Highlights from the Q2 2010 review of pharmaceutical and biotechnology dealmaking: Biopharma companies raised a total of $3.4bn through 96 financings. Twenty-one acquisitions together reached $20.2bn, thanks to five deals each exceeding $3 billion - in aggregate accounting for 91% of the M&A total. The alliance volume was up to 115 transactions for a total of $2.8 billion in pre-commercialization money, with seven deals surpassing the $100 million mark.
Abbott's India Plunge May Fetch Big Returns, But Integration Challenges, Growth Momentum Critical
Piramal Healthcare Chairman Ajay Piramal talks about the Indian pharmaceutical market after selling his domestic branded generics business to Abbott.
Despite European Nod, Novartis Gets FDA "Complete Response" For Indacaterol
FDA requests additional dosing information for the chronic obstructive pulmonary disorder drug, also known as QAB149.